VICTOR RIVERA to Prognosis
This is a "connection" page, showing publications VICTOR RIVERA has written about Prognosis.
Connection Strength
0.073
-
Single-Molecule Sequencing Reveals Patterns of Preexisting Drug Resistance That Suggest Treatment Strategies in Philadelphia-Positive Leukemias. Clin Cancer Res. 2018 11 01; 24(21):5321-5334.
Score: 0.018
-
Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. Blood. 2018 07 26; 132(4):393-404.
Score: 0.017
-
The impact of multiple low-level BCR-ABL1 mutations on response to ponatinib. Blood. 2016 Apr 14; 127(15):1870-80.
Score: 0.015
-
Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies. J Clin Oncol. 2008 Jan 20; 26(3):361-7.
Score: 0.009
-
Multiple sclerosis. Is the mystery beginning to unfold? Postgrad Med. 1986 Jun; 79(8):217-32.
Score: 0.008
-
The utility of MRI in suspected MS [RETIRED]: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2003 09 09; 61(5):602-11.
Score: 0.006